Articles tagged with Cancer Medication
Researchers at Ohio State University have identified a new protein, Pirh2, that diminishes the activity of p53, a powerful tumor suppressor. Overexpression of Pirh2 was found in 84% of human lung cancers and 93% of mouse tumors, suggesting its potential role in cancer development.
Researchers at Harvard University have developed a new method called cytological profiling that uses automated microscopic imaging to track the broad effects of drugs on cells. This technique allows for high-throughput analysis, enabling scientists to quickly identify promising drugs and streamline early phases of drug discovery.
Scientists at Johns Hopkins Medicine have identified Notch2 as a key gene target in childhood brain tumors, medulloblastoma. High levels of the Notch2 gene are associated with poorer outcomes and cancer cell growth promotion.
Researchers at Case Western Reserve University are developing predictive cancer models to target mismatch repair defective malignancies, which cause hereditary nonpolyposis colon cancer and other types of cancer. The goal is to better understand and predict tumor growth using genomics, proteomics, and molecular imaging.
Researchers developed a method combining CYP3A4 phenotyping with UGT1A1 genotyping to optimize irinotecan chemotherapy. Greater height, obesity, and lower physical activity levels are linked to increased endometrial cancer risk.
Researchers engineered human mesenchymal stem cells to target tumors, delivering a therapeutic gene that inhibits cancer growth. The approach significantly improved survival of mice with breast and melanoma cancers.
Researchers at the University of Pennsylvania School of Medicine have found a gene-silencing technique that induces cell death in drug-resistant CML cells. The technique targets the Lyn kinase enzyme, which is essential for cancerous blood cells to survive and grow.
Researchers at Summa Health System have discovered a new form of cell death in cancer cells, which could lead to improved treatment options. The novel therapeutic Apatone has shown promise in enhancing the performance of six different chemotherapeutic drugs and is currently being tested in clinical trials.
A new computational approach helps researchers understand the relationship between trait differences and variations in the mouse genome, moving closer to understanding human genetic differences. The method also has potential to uncover currently unknown genetic factors contributing to various diseases.
A new medication, nitric oxide-donating aspirin, has shown promise in preventing colon cancer by inhibiting the growth of colon cancer cells. The treatment is hundreds to thousands of times more potent than traditional aspirin and may reduce the risk of development by up to 95%.
A new study found that high birth weight is associated with an increased risk of childhood acute lymphoblastic leukemia (ALL) but not acute myeloid leukemia (AML). Researchers used data from health registers in four Nordic countries to conduct a case-control study involving over 2,000 children with ALL or AML and their siblings. They a...
A study found that antibiotics are ineffective in treating chronic prostate pain (CP/CPPS) but a-receptor blockers may provide relief for extended periods. Simple exercises improved dizziness in adults, while survivors of childhood cancer are at increased risk for breast cancer.
Allopurinol, commonly used for gout, was found to significantly reduce the risk of colorectal cancer in patients taking the medication for at least five years. The study analyzed data from 1,781 patients and showed a notable reduction in risk.
Consuming three or more servings of vegetables daily lowered NHL risk by 40% in study participants. Higher intakes of selenium and zinc also showed protective effects, while vitamins A-C-E and carotenoids had no significant link.
The new Mayo Clinic research indicates that mycophenolate mofetil could help many more lupus patients, offering a potential alternative to existing treatments with fewer side effects. Currently, there is no curative treatment for SLE, and many medications used to treat this disease have considerable side effects.
Researchers found a significant increase in ischemic stroke risk with tamoxifen, but emphasized that the absolute risk is small. The study's findings suggest careful screening of women before prescribing tamoxifen therapy due to potential stroke risk.
Researchers at Vanderbilt University Medical Center discovered that lithium can protect brain cells involved in learning and memory from radiation damage. Clinical trials are expected to test whether the drug can prevent cognitive deficits in humans treated with cranial radiation therapy.
A recent study published by Fox Chase Cancer Center found that patients who used nonsteroidal anti-inflammatory drugs (NSAIDs) regularly before their diagnosis and treatment had improved overall survival rates. The research involved 1,206 men with localized prostate cancer and compared the outcomes of those who used NSAIDs regularly to...
Researchers have discovered a cottonseed-derived compound that enhances the effectiveness of radiotherapy and chemotherapy in treating various cancers, including prostate cancer. The study's findings suggest that the compound, (-)-gossypol, can increase induction of apoptosis and make tumours more sensitive to radiation therapy.
Researchers at the University of Michigan have found that a potential small molecule inhibitor, (-)-gossypol, can boost the effectiveness of radiation therapy and chemotherapy in human prostate tumors in mice. The study demonstrates increased induction of apoptosis, making cancer cells more sensitive to treatment.
The second-generation antisense cancer drug OGX-011 has shown promising results in a Phase I trial, inhibiting clusterin production in patients' cancers. The Phase II trials will investigate the effectiveness of OGX-011 combined with standard chemotherapy in patients with metastatic hormone refractory prostate, breast, and lung cancer.
A study surveyed 605 women aged 40-69 to assess eligibility for tamoxifen-based breast cancer prevention. Only a small proportion of white women and none of black women were found to be at high risk, highlighting challenges in targeting discussions about chemoprevention.
A new study found that tamoxifen would only prevent a maximum of 6-8% of breast tumors in eligible women, while its harmful side effects rule out 90% of potential beneficiaries. The researchers suggest that other chemopreventive agents without the same side effects could be more effective in saving lives.
Yale researchers have been awarded a $7.5 million grant to investigate the role of viruses in cancer development. The grant will support studies on human papillomaviruses, Epstein-Barr Virus, and Kaposi's Sarcoma Herpesvirus, focusing on viral genes and cellular pathways that lead to cancer.
A recent study published in Carcinogenesis found that specific DNA patterns enhance breast cancer protection from marine n-3 fatty acids. Women with low-activity versions of genes associated with GSTs have a lower risk of breast cancer, while high-activity versions show no benefit.
Researchers tested the oral compound PKC412 in patients with Myeloproliferative Disease (MPD) and saw symptoms improve. The drug targets a specific genetic mutation, blocking abnormal tyrosine kinases that cause uncontrolled cell division and growth.
Researchers found that PGE2 activates PPARd through a signaling pathway promoting cell survival and polyp formation. This effect was not observed in mice lacking PPARd, highlighting the role of PPARd as a critical downstream mediator in PGE2-stimulated colorectal tumor growth.
Scientists successfully eliminated leukemia in genetically modified mice by disrupting the BCL-2 protein. The study provides strong support for a new paradigm of cancer treatment involving targeted apoptosis regulation.
Researchers have identified a protein tag that is unique to cancer cells and can be targeted by a drug delivery system. The strategy showed effectiveness in laboratory tests and animal models, and the team plans to test it next in human tumors.
Researchers at St. Jude Children's Research Hospital have successfully treated medulloblastoma brain cancer in lab models by targeting a single protein in the hedgehog pathway, demonstrating potential for novel treatment approaches and improved outcomes for patients.
Researchers in The Netherlands and Belgium developed a new technique that uses genetically engineered rhTSH to stimulate thyroid cancer cells to absorb radioactive iodine, avoiding hypothyroidism and increasing safety. This approach may allow higher doses of radioiodine to be used when needed, improving treatment efficacy.
Researchers found that combining histone deacetylase inhibitors with anti-angiogenesis drugs reduced tumor growth in mice by up to 85% and controlled new blood vessel formation by 60%. This combination therapy may provide a greater impact on cancer development than using the drugs alone.
Researchers found no clear association between atrazine exposure and cancer in a large cohort study. Additionally, studies on alcohol consumption and gastric cancer incidence revealed mixed results, while an animal study demonstrated the potential of mammaglobin-A immunotherapy as breast cancer treatment.
Researchers found that zoledronic acid inhibits the growth of cervical cancer by targeting macrophages expressing matrix metalloproteinase-9 (MMP-9) and angiogenesis. This treatment approach offers new hope for cervical cancer patients.
Researchers from MIT and international collaborations found that different proportions of two key ingredients in ginseng promote or hinder blood vessel growth, with implications for wound healing and cancer treatment. The study highlights the need for stronger regulations on herbal drugs due to variable processing methods.
Paediatric research is crucial for disease prevention and treatment, yet data are lacking due to a lack of legislation requiring companies to conduct trials on children. The UK Government's new initiative aims to invest £100 million in research networks but falls short of centre stage for acquiring research-based evidence.
Researchers have created a group of rhodium-based compounds that can target and kill cancer cells, as well as deactivate viruses like West Nile and yellow fever viruses. These compounds work by binding to DNA in tumor cells and rendering them inert, and they offer a promising alternative to traditional chemotherapy drugs.
Stanford researcher Matthew Bogyo and colleagues discovered that cathepsin cysteine proteases help build blood vessels to tumors, increase tumor growth and invasiveness. A broad-spectrum inhibitor slowed tumor development in mice with no apparent side effects.
Scientists have determined the precise molecular structure of a potential new target for treating prostate cancer, driven by abnormal testosterone activity. The target is part of the androgen receptor, which drives prostate cancer at different stages.
Researchers have discovered a significant correlation between ABC transporter gene expression and decreased sensitivity to certain cancer drugs. This study provides valuable insights into the role of these proteins in multidrug resistance, potentially leading to the development of new therapeutic strategies.
Researchers have uncovered a powerful new cancer-fighting property of Herceptin, which targets HER-2 positive breast cancer cells. The study found that high levels of PTEN in tumor cells predict response to the drug, and offers potential combination therapy with PI3K inhibitors.
Researchers at Johns Hopkins University have developed a new class of nitroxyl-releasing compounds that seem to strengthen cardiac contractions and relaxation in dogs with heart failure. These compounds, which produce nitric oxide (HNO), have shown promising results in early studies.
A new compound called OSU 111 has been developed to target both cancer cells and the formation of new blood vessels that feed them. In laboratory experiments, it was found to be highly effective in killing prostate cancer tissue cells within three days.
Researchers developed first mouse embryos without D-type cyclins, which sparked hope for anti-cancer therapy. The triple-knockout mice followed a normal course of cell division until late stages, contradicting previous theory and experiments.
A national study led by UC Davis researchers found that surveillance colonoscopies are performed more frequently than necessary, with 24% of gastroenterologists recommending unnecessary procedures. The study suggests that implementation of clinical guidelines can help optimize patient care and reduce healthcare burden.
Emory researchers create three-dimensional, atomic-scale images of epothilone A binding site with key protein controlling cell division. The study's results pave the way for creating new compounds and a clinical tool for pharmacogenetic profiling.
MGH cancer specialists propose a new 'selective approval' mechanism to identify most suitable patients for targeted therapies. This approach could improve treatment outcomes and reduce waste of resources.
Researchers have developed a new approach to identify connections between genes and chemotherapy drugs, which may enable clinicians to customize treatment plans. By analyzing cell lines from large families, the team found potential links between genetic markers and increased sensitivity to two chemotherapy drugs.
A recent study found that combining EGFR inhibitors like Erbitux with Iressa or Tarceva hinders cancer cell growth more effectively than single drug treatments. The tandem application of these drugs amplified control of cancer cell signaling, leading to increased apoptosis and tumor development limitation.
Researchers have identified nearly 100 genes linked to cancer, shedding light on the processes driving disease progression. The study highlights the potential of targeted therapies and early detection methods to manage cancer.
The NIH has renewed funding for Giordano's Rb2 tumor suppressing gene research at Temple University, aiming to design therapies for cancer patients. Over the past decade, Giordano's work linked Rb2 with cancer regression and effectiveness of drug therapies against breast cancer.
The award honors an individual scientist for highly original research, with the winner receiving €75,000 and a commemorative plaque. Recent past recipients include Stanley J. Korsmeyer and Mario R. Capecchi.
The American Association for Cancer Research (AACR) is honoring outstanding scientists and physicians who have made significant contributions to cancer research. The AACR recognizes researchers in various fields, including basic cancer research, clinical cancer research, and medical chemistry.
A new phase 2 study shows that combining cetuximab with irinotecan can resensitize tumors resistant to irinotecan, offering patients a new treatment option. The study's modest benefits in stopping cancer growth and improving patient response are seen as a step forward in treating colorectal cancer.
A study published in Cancer Cell reveals that mouse cells lacking LKB1 and PJS mouse polyps show activation of molecules downstream of the mTOR protein. Researchers suggest that using mTOR inhibitors like rapamycin may be useful for treating PJS patients' polyps and potentially other tumors resulting from LKB1 loss.
Researchers have discovered that N-acetylcysteine (NAC) can prevent cisplatin-induced ototoxicity, a type of progressive and irreversible hearing loss in patients undergoing chemotherapy for head and neck cancer. The study found that NAC was most effective when given 15 minutes before chemotherapy.
A study published in Science reports the effectiveness of a new compound, BMS-354825, against Gleevec-resistant Chronic Myeloid Leukemia (CML) cells. The compound targets secondary mutations that allow cancer to evade therapy, offering hope for patients who have relapsed on Gleevec.
Researchers find that combining discodermolide and paclitaxel inhibits human lung cancer cell growth by 41 percent, while alone the drugs exert only 9.6% or 16% growth inhibition. The combination also induces programmed cell death in cancer cells, suggesting a potential therapeutic approach for reducing undesirable side effects.
Researchers have identified a new compound, BMS-354825, that successfully sidesteps the problem of Gleevec resistance in some patients. The compound prolongs survival of mice with chronic myeloid leukemia (CML) and inhibits the proliferation of bone marrow progenitor cells resistant to Gleevec.
Researchers at Ohio State University developed a new anti-cancer agent, OSU-03012, which inhibits Akt and induces programmed cell death in cancer cells. The agent has shown potent activity against various types of cancer, including leukemia and breast and lung cancers.